ARTICLE | Company News
Dendreon sales and marketing update
April 6, 2015 7:00 AM UTC
The U.K.’s NICE issued final guidance recommending against the use of Dendreon’s Provenge sipuleucel-T to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC) in adults when chemotherapy is not yet clinically indicated -- its approved indication. NICE said the incremental cost-effectiveness ratio (ICER) for Provenge was “well above” the range considered a cost-effective use of NHS resources. The final guidance is in line with a preliminary appraisal issued last October and a final appraisal determination (FAD) issued in January (see BioCentury, Oct. 20, 2014). ...